SUPPORTING INFECTIOUS DISEASE RESEARCH

### Pseudomonas aeruginosa, Strain MRSN 15678

### Catalog No. NR-51579

This reagent is the tangible property of the U.S. Government.

### **Product Description:**

*Pseudomonas aeruginosa (P. aeruginosa)*, strain MRSN 15678 was isolated in 2013 from a human wound as part of a surveillance program in the United States. *P. aeruginosa*, strain MRSN 15678 was deposited as sensitive to amikacin, gentamicin and tobramycin, intermediately resistant to aztreonam and cefepime and resistant to ceftazidime, ciprofloxacin, imipenem, levofloxacin, meropenem and piperacillin/tazobactam.

### Lot: 70025064<sup>1</sup>

## Manufacturing Date: 28JUN2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology <sup>2</sup>	Report results	Circular, convex, undulate, smooth and green (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	P. aeruginosa (≥ 89%)	P. aeruginosa (≥ 98%)
Antibiotic Susceptibility Profile <sup>3</sup> VITEK <sup>®</sup> (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant ( $\geq$ 32 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Intermediate (16 µg/mL) <sup>4</sup>
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Intermediate	Intermediate (16 µg/mL)
Meropenem	Resistant	Intermediate (4 µg/mL) <sup>5</sup>
Amikacin	Sensitive	Sensitive (8 µg/mL)
Gentamicin	Sensitive	Sensitive (4 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 320 µg/mL <sup>6</sup>
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	100% sequence identity to
(~ 1420 base pairs)	<i>P. aeruginosa</i> , strain MRSN 15678 (GenBank: RXVZ01000134.1)	<i>P. aeruginosa</i> , strain MRSN 15678 (GenBank: RXVZ01000134.1)
Purity (post-freeze) <sup>7</sup>	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze) <sup>2</sup>	Growth	Growth

<sup>1</sup>NR-51579 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.
<sup>2</sup>1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

<sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>4</sup>P. aeruginosa, strain MRSN 15678 was deposited as resistant to ceftazidime. Repeated antibiotic susceptibility testing determined that strain MRSN 15678 is intermediately resistant to ceftazidime.

<sup>5</sup>Susceptibilty results for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

# **Certificate of Analysis for NR-51579**

#### SUPPORTING INFECTIOUS DISEASE RESEARCH

<sup>6</sup>Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.
<sup>7</sup>Purity of this lot was assessed for 8 days at 37°C in an aerobic atmosphere with and without 5% CO<sub>2</sub> on Tryptic Soy agar.

### Figure 1: Colony Morphology



# /Heather Couch/ Heather Couch

### 11 DEC 2019

Program Manager or designee, ATCC Federal Solutions

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

